Scilex Holding Company

Henry Ji filed Amendment No. 5 to his Schedule 13D on DataVault AI Inc. (issuer) as of August 20, 2026. Ji is based in Palo Alto at 960 San Antonio Rd. Routine activist or significant holder position update in DataVault AI; specific changes to his stake or intent are in the full amendment body not captured in the excerpt.

Scilex Holding Company (SCLX) filed an 8-K on August 13, 2026 (event date August 8) under Item 1.01, announcing a material definitive agreement. The excerpt is the cover page; the specific agreement terms and counterparty details are in the body. Scilex develops non-opioid pain management products, including ZTlido lidocaine patches. Material definitive agreements for specialty pharma companies often involve licensing, development collaborations, or royalty transactions.

Scilex Holding Company entered into a stock repurchase agreement with Vivasor Holding Company on July 18, 2026, under which Scilex agreed to sell back to Vivasor 6,101,468 shares of Vivasor Series A-1 Preferred Stock and 355,919 shares of Vivasor Series A-2 Preferred Stock — shares that Scilex had previously acquired from Vivasor. This transaction is disclosed under both Item 1.01 (material definitive agreement) and Item 2.01 (completion of acquisition or disposition of assets), indicating the deal has closed or is substantially complete. The disposition of Vivasor preferred stock by Scilex signals a strategic unwind of a prior investment position in a private company; dollar consideration is not visible in the excerpt but would be in the full exhibit.

SCLX Stock Acquisition JV LLC (managed by Xiao Xu, Palo Alto CA) filed Amendment No. 6 to its Schedule 13D for Scilex Holding Company as of July 3, 2026, reflecting a change in position or intent by this activist/large-holder entity. This is a recurring activist holder update for Scilex — the sixth amendment signals ongoing strategic interest or positioning changes by this entity in the clinical-stage pain therapeutics company.

Scilex Holding Company signed a binding term sheet on July 3, 2026 with iHolding Group LLP (Kazakhstan-based private investment group) for a $100 million equity investment at $15.00 per share (approximately 6,666,667 new shares). The proposed investment remains subject to definitive agreements, board approval, stockholder approval, and regulatory approvals — no assurance of closing was provided. At $15.00 per share with current market prices, this could represent either a premium or discount depending on trading levels; it would be materially dilutive if consummated.

Scilex Holding entered a binding term sheet to purchase Bitcoin from Datavault AI Inc. (sourced from a Biconomy digital wallet), subject to execution of a definitive purchase agreement. This speculative treasury diversification move by a small commercial pharma company reflects the retail-driven trend of non-crypto companies adopting Bitcoin as a treasury asset. Final purchase remains subject to definitive documentation.

Scilex Holding Company (SCLX) filed Amendment No. 2 to its Schedule 13D on Semnur Pharmaceuticals, Inc. as of June 15, 2026, reporting aggregate beneficial ownership of 181,520,112 shares — 78.85% of Semnur's outstanding common stock. The stake is held through wholly-owned subsidiary Scilex, Inc. (174,770,112 shares) and Scilex Bio, Inc. (6,250,000 shares), plus 500,000 shares held directly; SCLX also holds 100% of Semnur's Series A Preferred Stock voting on an as-converted basis. SCLX's 78.85% majority ownership of Semnur reflects dominant post-business-combination control over Semnur's assets and pipeline.

Scilex Holding Company held its 2026 Annual Meeting on June 24, 2026 with ~63.5% of common shares and 100% of Series A preferred stock represented (preferred votes on as-converted basis for ~848K aggregate votes). Three proposals were on the ballot; the high preferred stock concentration is a structural note for common shareholders. Body unavailable — excerpt truncated before full vote results are disclosed.